OXNARD, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs), today announces the appointment of Jessica Rousset, 40, as chief business officer.
“It is a privilege to be joining CURE Pharmaceutical at this time of growth,” said Ms. Rousset. “The organization is uniquely positioned to transform the way medicines are delivered across many therapeutic areas and patient populations.”
Ms. Rousset brings more than fifteen years of experience fostering innovation in large organizations and advising start-ups to bring novel healthcare solutions to market and into clinical use. She previously served as head of innovation at Children's Hospital Los Angeles, where over a ten-year period, she helped launch both therapeutic and medical device companies and founded and operated a national pediatric technology accelerator. Prior to that, she held positions at The Scripps Research Institute and GlaxoSmithKline Biologicals in laboratory, clinical research and business development roles.
Ms. Rousset trained as a biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France. She currently resides in Los Angeles with her husband and two children.
“Jessica has an impressive business development track record, from significant expansion of Children’s Hospital Los Angeles’s innovation center to her time within the biotechnology and medical device industries,” said Rob Davidson, CEO of CURE Pharmaceutical. “As we enter a critical period in our corporate development, we are excited to have Jessica help complete the management team, and provide additional focus in our business development activities.”
About CURE Pharmaceutical Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility. CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com .
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.com
